Juan José Castón1,2, Sara Cantisán3,4, Francisco González-Gasca1, Aurora Páez-Vega5, Hasania Abdel-Hadi6, Soledad Illescas7, Gema Alonso8, Julián Torre-Cisneros2,5. 1. Unit of Infecious Diseases, Department of Internal Medicine, Hospital General Universitario, Universidad de Castilla La Mancha, Ciudad Real, Spain. 2. Spanish Network for the Research in Infectious Diseases (REIPI RD12/0015), Madrid, Spain. 3. Spanish Network for the Research in Infectious Diseases (REIPI RD12/0015), Madrid, Spain. sacanti@hotmail.com. 4. Clinical Unit of Infectious Diseases, Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), Reina Sofía University Hospital, University of Cordoba, Avda, Menéndez Pidal s/n, 14004, Cordoba, Spain. sacanti@hotmail.com. 5. Clinical Unit of Infectious Diseases, Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), Reina Sofía University Hospital, University of Cordoba, Avda, Menéndez Pidal s/n, 14004, Cordoba, Spain. 6. Intensive Care Unit, Hospital General Universitario, Ciudad Real, Spain. 7. Service of Microbiology, Hospital General Universitario, Ciudad Real, Spain. 8. Intensive Care Unit, Hospital Universitario Reina Sofía, Cordoba, Spain.
Abstract
PURPOSE: To evaluate the usefulness of the secretion of interferon-γ (IFNγ) by cytomegalovirus (CMV)-specific CD8+ T cells to determine the risk of CMV reactivation in critically ill non-immunosuppressed patients. METHODS: Two-center prospective cohort study including critically ill non-immunosuppressed CMV-seropositive patients admitted between December 2012 and March 2013. The incidence of CMV reactivation by polymerase chain reaction (real-time PCR) in plasma was investigated. IFNγ secretion by CMV-specific CD8+ T lymphocytes was determined at the time of admission to the intensive care unit (ICU) by means of the QuantiFERON(®)-CMV (QF-CMV) test. Cox regression analyses were performed to investigate CMV reactivation risk factors. RESULTS: Fifty-three patients were included, of whom 13 (24.5%) presented CMV reactivation. Twenty-six patients (49.1%) were QF-CMV "reactive" (QF-CMV(R)). Of the 26 QF-CMV(R) patients, 11.5% (3/26) had CMV reactivation, whereas 37% (10/27) of QF-CMV "non reactive" patients (QF-CMV(NR)) presented reactivation (p = 0.03). By Cox regression, the presence of QF-CMV(R) at ICU admission (HR 0.09, 95% CI 0.02-0.44; p = 0.003) was associated with a decreased risk of CMV reactivation. The sensitivity, specificity, positive predictive value, and negative predictive value of QF-CMV were 77, 57, 37, and 88%, respectively. Eleven of the 53 patients (20.7%) died during the follow-up period. Mortality was more frequent in patients with CMV reactivation (6/13, 46.1 vs. 5/40, 12.5%; p = 0.015). CONCLUSIONS: In critically ill non-immunosuppressed patients, the presence of functional CMV-specific CD8+ T lymphocyte response at intensive care unit admission provides protection against CMV reactivation.
PURPOSE: To evaluate the usefulness of the secretion of interferon-γ (IFNγ) by cytomegalovirus (CMV)-specific CD8+ T cells to determine the risk of CMV reactivation in critically ill non-immunosuppressed patients. METHODS: Two-center prospective cohort study including critically ill non-immunosuppressed CMV-seropositive patients admitted between December 2012 and March 2013. The incidence of CMV reactivation by polymerase chain reaction (real-time PCR) in plasma was investigated. IFNγ secretion by CMV-specific CD8+ T lymphocytes was determined at the time of admission to the intensive care unit (ICU) by means of the QuantiFERON(®)-CMV (QF-CMV) test. Cox regression analyses were performed to investigate CMV reactivation risk factors. RESULTS: Fifty-three patients were included, of whom 13 (24.5%) presented CMV reactivation. Twenty-six patients (49.1%) were QF-CMV "reactive" (QF-CMV(R)). Of the 26 QF-CMV(R) patients, 11.5% (3/26) had CMV reactivation, whereas 37% (10/27) of QF-CMV "non reactive" patients (QF-CMV(NR)) presented reactivation (p = 0.03). By Cox regression, the presence of QF-CMV(R) at ICU admission (HR 0.09, 95% CI 0.02-0.44; p = 0.003) was associated with a decreased risk of CMV reactivation. The sensitivity, specificity, positive predictive value, and negative predictive value of QF-CMV were 77, 57, 37, and 88%, respectively. Eleven of the 53 patients (20.7%) died during the follow-up period. Mortality was more frequent in patients with CMV reactivation (6/13, 46.1 vs. 5/40, 12.5%; p = 0.015). CONCLUSIONS: In critically ill non-immunosuppressed patients, the presence of functional CMV-specific CD8+ T lymphocyte response at intensive care unit admission provides protection against CMV reactivation.
Authors: Michael Boeckh; W Garrett Nichols; Roy F Chemaly; Genovefa A Papanicolaou; John R Wingard; Hu Xie; Karen L Syrjala; Mary E D Flowers; Terry Stevens-Ayers; Keith R Jerome; Wendy Leisenring Journal: Ann Intern Med Date: 2015-01-06 Impact factor: 25.391
Authors: L M A J Muller; K J Gorter; E Hak; W L Goudzwaard; F G Schellevis; A I M Hoepelman; G E H M Rutten Journal: Clin Infect Dis Date: 2005-06-16 Impact factor: 9.079
Authors: David S Y Ong; Peter M C Klein Klouwenberg; Frans M Verduyn Lunel; Cristian Spitoni; Jos F Frencken; Huberta A T Dekker; Marcus J Schultz; Marc J M Bonten; Olaf L Cremer Journal: Crit Care Med Date: 2015-02 Impact factor: 7.598
Authors: S Cantisán; R Lara; M Montejo; J Redel; A Rodríguez-Benot; J Gutiérrez-Aroca; M González-Padilla; L Bueno; A Rivero; R Solana; J Torre-Cisneros Journal: Am J Transplant Date: 2013-01-11 Impact factor: 8.086
Authors: F M Mattes; A Vargas; J Kopycinski; E G Hainsworth; P Sweny; G Nebbia; A Bazeos; M Lowdell; P Klenerman; R E Phillips; P D Griffiths; V C Emery Journal: Am J Transplant Date: 2008-03-04 Impact factor: 8.086
Authors: Alexandra Heininger; Helene Haeberle; Imma Fischer; Robert Beck; Reimer Riessen; Frank Rohde; Christoph Meisner; Gerhard Jahn; Alfred Koenigsrainer; Klaus Unertl; Klaus Hamprecht Journal: Crit Care Date: 2011-03-01 Impact factor: 9.097
Authors: Siok-Keen Tey; Glen A Kennedy; Deborah Cromer; Miles P Davenport; Susan Walker; Linda I Jones; Tania Crough; Simon T Durrant; James A Morton; Jason P Butler; Ashish K Misra; Geoffrey R Hill; Rajiv Khanna Journal: PLoS One Date: 2013-10-11 Impact factor: 3.240
Authors: Carrianne J Leschak; Janine M Dutcher; Kate E Byrne Haltom; Elizabeth C Breen; Julienne E Bower; Naomi I Eisenberger Journal: Psychol Health Date: 2021-11-17
Authors: Craig M Coopersmith; Daniel De Backer; Clifford S Deutschman; Ricard Ferrer; Ishaq Lat; Flavia R Machado; Greg S Martin; Ignacio Martin-Loeches; Mark E Nunnally; Massimo Antonelli; Laura E Evans; Judith Hellman; Sameer Jog; Jozef Kesecioglu; Mitchell M Levy; Andrew Rhodes Journal: Intensive Care Med Date: 2018-07-03 Impact factor: 17.440